AACR Congratulates Members Elected to the National Academy of Medicine
10 members of the AACR elected, including Fellow of the AACR Academy Drew Pardoll, MD, PhD PHILADELPHIA – The...
Search/Filter
Loading...
AACR Announces Official Call for Papers for New Open Access Journal, Cancer Research Communications
PHILADELPHIA — The American Association for Cancer Research (AACR) today announced the opening of the submission site for its...
AACR Sends Letter to CDC Director Urging Boosters for Caregivers and Household Members to Protect Patients with Cancer
Patients with cancer may not receive full benefit of vaccination and are at higher risk for severe illness and...
AACR Launches Two Career Development Awards to Encourage Diversity in the Cancer Research Workforce
PHILADELPHIA – Today, the American Association for Cancer Research (AACR) announced the creation of two career development awards (CDAs)...
AACR Cancer Progress Report Highlights How Discovery Science is Driving Clinical Breakthroughs
Fifty years after the signing of the National Cancer Act, rapid progress against cancer for patients continues Medical research...
AACR Expresses Sincere Appreciation to NIH Director Francis Collins
PHILADELPHIA — The American Association for Cancer Research (AACR) today expressed its gratitude to Francis S. Collins, MD, PhD,...
A Peptide-drug Conjugate that Targets the Acidic Environment of Cancer Cells May Improve the Efficacy of Immunotherapy
PHILADELPHIA – A peptide-drug conjugate that targets the acidic environment of cancer cells enhanced the efficacy of immune checkpoint...
Inhibition of the Aurora Kinase A Protein May Help Overcome Lung Cancer Resistance to KRAS Inhibition
PHILADELPHIA – In preclinical models, combining an investigational Aurora Kinase A (AURKA) inhibitor with a KRAS inhibitor or a...
Adding ErbB Tyrosine Kinase Inhibitor to KRAS Inhibitor May Help Circumvent Lung Cancer Resistance to Prior Therapies
PHILADELPHIA – Combination of the KRAS inhibitor sotorasib (Lumakras) with afatinib, a pan-ErbB tyrosine kinaseinhibitor, was feasible in treating...
DNA Alkylation Drug May Improve Outcomes for Adolescents and Young Adults With Central Nervous System Tumors
PHILADELPHIA – In a phase II clinical trial, the drug 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) improved survival for some adolescent and young...